Join Gary Cole, a patient with advanced RCC, as he discusses his transformative experience with Belzutifan, a groundbreaking drug recently approved for advanced renal cell carcinoma, with Dr. Hans Hammers of UT Southwestern.

Belzutifan's recent FDA approval began decades ago at UTSW (more on that here: https://www.utsouthwestern.edu/newsro....

Learn how Belzutifan, a HIF-2α inhibitor, has made significant strides in the treatment of kidney cancer, especially for patients with disease progression after standard therapies. Gary's story is not just about medical treatment; it's about hope, resilience, and the ongoing quest for better cancer care. Gary discusses some of his previous experiences with standard therapies and his decision to participate in a clinical trial.

This video is a must-watch for patients, caregivers, and anyone interested in the latest advancements in kidney cancer treatment. Don't forget to submit your questions and join the conversation about this revolutionary drug.